Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common stock ("Common Shares")
-
Shares outstanding
-
212,883,456
-
Number of holders
-
146
-
Total 13F shares, excl. options
-
50,434,472
-
Shares change
-
+9,779,634
-
Total reported value, excl. options
-
$1,043,919,487
-
Value change
-
+$206,608,703
-
Put/Call ratio
-
39%
-
Number of buys
-
91
-
Number of sells
-
-43
-
Price
-
$20.70
Significant Holders of OCULAR THERAPEUTIX, INC - Common stock ("Common Shares") (OCUL) as of Q4 2020
165 filings reported holding OCUL - OCULAR THERAPEUTIX, INC - Common stock ("Common Shares") as of Q4 2020.
OCULAR THERAPEUTIX, INC - Common stock ("Common Shares") (OCUL) has 146 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 50,434,472 shares
of 212,883,456 outstanding shares and own 24% of the company stock.
Largest 10 shareholders include Opaleye Management Inc. (6,510,000 shares), SUMMER ROAD LLC (5,618,861 shares), BlackRock Inc. (5,512,264 shares), VANGUARD GROUP INC (3,549,998 shares), DELTEC ASSET MANAGEMENT LLC (2,168,573 shares), CITADEL ADVISORS LLC (1,588,874 shares), Versant Venture Management, LLC (1,465,384 shares), STATE STREET CORP (1,454,954 shares), EMERALD ADVISERS, LLC (1,190,703 shares), and EMERALD MUTUAL FUND ADVISERS TRUST (1,121,628 shares).
This table shows the top 146 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.